Time-selective chemoprevention of vitamin e and selenium on esophageal carcinogenesis in rats: The possible role of nuclear factor kappaB signaling pathway

International Journal of Cancer

Volumn 131, Issue 7, 2012, Pages 1517-1527

  Yang, Hui ^a   Jia, Xudong ^a   Chen, Xiaoxin ^b   Yang, Chung S ^c   Li, Ning ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

chemoprevention; esophageal cancer; N nitrosomethylbenzylamine; selenium; vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE B4; PROSTAGLANDIN E2; SELENIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DYSPLASIA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CARCINOMA; GENE EXPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AMINO ACIDS; ANIMALS; BIOLOGICAL MARKERS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DIETARY SUPPLEMENTS; DIMETHYLNITROSAMINE; ESOPHAGEAL NEOPLASMS; INFLAMMATION; MALE; NF-KAPPA B; NUTRITIONAL STATUS; RATS; RATS, INBRED F344; SELENIUM; SIGNAL TRANSDUCTION; TIME FACTORS; VITAMIN E;

EID: 84864449352     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27423     Document Type: Article

References (50)

1. Hongo M, Nagasaki Y, Shoji T,. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009; 24: 729-35.
2. Eslick GD,. Epidemiology of esophageal cancer. Gastroenterol Clin North Am 2009; 38: 17-25, vii.
3. Wattenberg LW,. Chemoprevention of cancer. Cancer Res 1985; 45: 1-8.
4. Morse MA, Stoner GD,. Cancer chemoprevention: principles and prospects. Carcinogenesis 1993; 14: 1737-46.
5. Zou XN, Taylor PR, Mark SD, Chao A, Wang W, Dawsey SM, Wu YP, Qiao YL, Zheng SF,. Seasonal variation of food consumption and selected nutrient intake in Linxian, a high risk area for esophageal cancer in China. Int J Vitam Nutr Res 2002; 72: 375-82.
6. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, Yu Y, Liu B,. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483-92.
7. Taylor PR, Li B, Dawsey SM, Li JY, Yang CS, Guo W, Blot WJ,. Prevention of esophageal cancer: the nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group. Cancer Res 1994; 54: 2029s-2031s.
8. Wang GQ, Dawsey SM, Li JY, Taylor PR, Li B, Blot WJ, Weinstein WM, Liu FS, Lewin KJ, Wang H,. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the General Population Trial in Linxian, China. Cancer Epidemiol Biomarkers Prev 1994; 3: 161-6.
9. Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, Sun XD, Johnson LL, Gail MH, Dong ZW, Yu B, Mark SD, Taylor PR,. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst 2009; 101: 507-18.
10. Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, Guo W, Liu SF, Yang CS, Shen Q, Wang W, Mark SD, Zou XN, Greemwald P, Wu PY, Blot WJ,. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 1993; 85: 1492-8.
11. Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, Giffen CA, Wang G, Roth MJ, Lu N, Korn EL, Ma Y, et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 2005; 129: 863-73.
12. Wright ME, Virtamo J, Hartman AM, Pietinen P, Edwards BK, Taylor PR, Huttunen JK, Albanes D,. Effects of alpha-tocopherol and beta-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial. Cancer 2007; 109: 891-8.
13. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, III, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
14. Allen NE, Key TJ,. Prostate cancer: neither vitamin E nor selenium prevents prostate cancer. Nat Rev 2009; 6: 187-8.
15. Klein EA, Thompson IM, Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-56.
16. Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, Estaquio C, Hercberg S,. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 2005; 116: 182-6.
17. Stevens VL, McCullough ML, Diver WR, Rodriguez C, Jacobs EJ, Thun MJ, Calle EE,. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control 2005; 16: 643-50.
18. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007; 297: 2351-9.
19. Kim YI,. Folate, colorectal carcinogenesis, and DNA methylation: lessons from animal studies. Environ Mol Mutagen 2004; 44: 10-25.
20. Ulrich CM, Potter JD,. Folate and cancer-timing is everything. JAMA 2007; 297: 2408-9.
21. Stoner GD, Gupta A,. Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 2001; 22: 1737-46.
22. Yang H, Fang J, Jia X, Han C, Chen X, Yang CS, Li N,. Chemopreventive effects of early-stage and late-stage supplementation of vitamin E and selenium on esophageal carcinogenesis in rats maintained on a low vitamin E/selenium diet. Carcinogenesis 2011; 32: 381-8.
23. Reeves PG, Nielsen FH, Fahey GC, Jr,. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993; 123: 1939-51.
24. Pozharisski KM,. Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the oesophagus. IARC Sci Publ 1990: 109-28.
25. Wan SG, Taccioli C, Jiang Y, Chen H, Smalley KJ, Huang K, Liu XP, Farber JL, Croce CM, Fong LY,. Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression. Int J Cancer 2011; 129: 331-45.
26. Li N, Sood S, Wang S, Fang M, Wang P, Sun Z, Yang CS, Chen X,. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 2005; 11: 2089-96.
27. Chen X, Sood S, Yang CS, Li N, Sun Z,. Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention. Curr Cancer Drug Targets 2006; 6: 613-22.
28. Stoner GD, Chen T, Kresty LA, Aziz RM, Reinemann T, Nines R,. Protection against esophageal cancer in rodents with lyophilized berries: potential mechanisms. Nutr Cancer 2006; 54: 33-46.
29. Chen T, Hwang H, Rose ME, Nines RG, Stoner GD,. Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun. Cancer Res 2006; 66: 2853-9.
30. Clark LC, Dalkin B, Krongrad A, Combs GF, Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998; 81: 730-4.
31. Klein EA, Lippman SM, Thompson IM, Goodman PJ, Albanes D, Taylor PR, Coltman C,. The selenium and vitamin E cancer prevention trial. World J Urol 2003; 21: 21-7.
32. Luo JL, Kamata H, Karin M,. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-32.
33. Karin M, Ben-Neriah Y,. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-63.
34. Hayden MS, Ghosh S,. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-224.
35. Mantovani A, Allavena P, Sica A, Balkwill F,. Cancer-related inflammation. Nature 2008; 454: 436-44.
36. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y,. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
37. Karin M, Cao Y, Greten FR, Li ZW,. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev 2002; 2: 301-10.
38. Zhi H, Zhang J, Hu G, Lu J, Wang X, Zhou C, Wu M, Liu Z,. The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. Int J Cancer 2003; 106: 327-33.
39. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C,. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007; 121: 2381-6.
40. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K,. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.
41. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, Sugihara K,. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998; 58: 4823-6.
42. Tjandrawinata RR, Dahiya R, Hughes-Fulford M,. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997; 75: 1111-18.
43. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ,. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929-34.
44. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN,. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
45. Corley DA, Kerlikowske K, Verma R, Buffler P,. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56.
46. Matsuyama M, Yoshimura R,. Arachidonic acid pathway: a molecular target in human testicular cancer (Review). Mol Med Rep 2009; 2: 527-31.
47. Steele VE, Hawk ET, Viner JL, Lubet RA,. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 2003; 523/524: 137-44.
48. Sclabas GM, Uwagawa T, Schmidt C, Hess KR, Evans DB, Abbruzzese JL, Chiao PJ,. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 2005; 103: 2485-90.
49. Futakuchi M, Ogawa K, Tamano S, Takahashi S, Shirai T,. Suppression of metastasis by nuclear factor kappaB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. Cancer Sci 2004; 95: 18-24.
50. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA,. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007; 99: 545-57.